Immatics N.V. (IMTX) stock surged 5.80% in after-hours trading on Monday, following an analyst upgrade from Goldman Sachs. Analyst Rajan Sharma initiated coverage on Immatics with a Buy rating and set a price target of $13.50 per share, implying significant upside from current levels.
Sharma cited Immatics' promising pipeline of immunotherapies and innovative technologies as key reasons for the bullish outlook. The analyst believes the company's ACTengine platform could drive success in developing novel treatments for solid tumors, a major unmet medical need.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments